---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-023288"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:35:00.497360+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M

## Summary
- Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).
- Cash and restricted cash $18.9M at Dec 31, 2025 ($58.8M year-end 2024); January 2026 raised $22.5M via stock offering led by RTW Investments.
- OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa completed enrollment (140 patients); topline data expected Q1 2027.
- OCU410ST Phase 2/3 GARDian trial nearing enrollment completion; interim data Q3 2026; OCU410 Phase 2 showed 46% lesion growth reduction.
- Exclusive Korean rights to OCU400 licensed to Kwangdong Pharmaceutical with upfront fees and milestones.

## SEC filing metadata
- accession: 0001104659-26-023288
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/0001104659-26-023288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-023288
- JSON: https://secwatch.observer/filing/0001104659-26-023288.json
- Plain text: https://secwatch.observer/filing/0001104659-26-023288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.